What is Psyomics?
Founded in 2015 by Professor Sabine Bahn of the University of Cambridge and CEO Dan Cowell, Psyomics operates at the intersection of academic research and commercial healthcare technology. The company specializes in developing sophisticated diagnostic solutions aimed at improving the speed and precision of mental health assessments. By translating complex biological and clinical data into actionable insights, Psyomics addresses the critical need for objective diagnostic markers in a field historically reliant on subjective reporting. Its market position is bolstered by its deep roots in the Cambridge innovation ecosystem, allowing it to bridge the gap between laboratory-based discovery and clinical application.
How much funding has Psyomics raised?
Psyomics has raised a total of $10M across 3 funding rounds:
Unspecified
$2M
Unspecified
$2.9M
Other Financing Round
$5.1M
Unspecified (2020): $2M with participation from Cambridge Enterprise, Parkwalk Advisors Limited, Jonathan Milner, and Martlet
Unspecified (2022): $2.9M led by Parkwalk
Other Financing Round (2024): $5.1M supported by Parkwalk Advisors
Key Investors in Psyomics
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. They bridge the gap between academic research and commercial success by providing funding and expertise to ventures in sectors such as HealthTech.
Cambridge Enterprise
The commercialization arm of the University of Cambridge, dedicated to supporting the translation of academic research into impactful commercial ventures.
Martlet
An early-stage investment firm that provides capital and strategic support to high-growth technology companies, often focusing on the Cambridge innovation cluster.
What's next for Psyomics?
With this latest round of financing, Psyomics is well-positioned to scale its operations and expand its clinical footprint. The strategic focus will likely center on the commercialization of its diagnostic platform, potentially moving toward broader integration within healthcare systems. As the company transitions from development to widespread clinical adoption, the focus will shift toward validating its diagnostic accuracy across diverse patient populations and securing regulatory milestones. This capital provides the necessary runway to refine its technological infrastructure and strengthen its competitive advantage in the rapidly evolving HealthTech landscape.
See full Psyomics company page
